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ABSTRACT 
Functional magnetic resonance imaging (fMRI) can be combined with drugs to 
investigate the system-level functional responses in the brain to such challenges. 
However, most psychoactive agents act on multiple neurotransmitters, limiting the 
ability of fMRI to identify functional effects related to actions on discrete 
pharmacological targets. We recently introduced a multimodal approach, REACT 
(Receptor-Enriched Analysis of functional Connectivity by Targets), which offers the 
opportunity to disentangle effects of drugs on different neurotransmitters and clarify 
the biological mechanisms driving clinical efficacy and side effects of a compound. 
Here, we focus on methylphenidate (MPH), which binds to the dopamine transporter 
(DAT) and the norepinephrine transporter (NET), to unravel its effects on 
dopaminergic and noradrenergic functional circuits in the healthy brain at rest. We 
then explored the relationship between these target-enriched resting state functional 
connectivity (FC) maps and inter-individual variability in behavioural responses to a 
reinforcement-learning task encompassing a novelty manipulation to disentangle the 
molecular systems underlying specific cognitive/behavioural effects. 
Our main analysis showed a significant MPH-induced FC increase in sensorimotor 
areas in the functional circuit associated with DAT. In our exploratory analysis, we 
found that MPH-induced regional variations in the DAT and NET-enriched FC maps 
were significantly correlated with some of the inter-individual differences on key 
behavioural responses associated with the reinforcement-learning task. 
Our findings show that main MPH-related FC changes at rest can be understood 
through the distribution of DAT in the brain. Furthermore, they suggest that when 
compounds have mixed pharmacological profiles, REACT may be able to capture 
regional functional effects that are underpinned by the same cognitive mechanism 
but are related to engagement of distinct molecular targets. 
  
INTRODUCTION 
Methylphenidate (MPH) is a psychostimulant medication widely used to treat 
attention deficit hyperactivity disorder (ADHD), a mental health disorder 
characterised by behavioural symptoms including impulsiveness, hyperactivity and 
inattention [1,2]. In a recent network meta-analysis, MPH, as compared to placebo, 
was shown to decrease the core ADHD symptoms in children, adolescents and 
adults with a moderate effect size between 0.49-0.78 [3]. Though MPH has been used 
for more than half a century, we still lack a clear understanding of the exact 
neurochemical mechanisms through which it exerts its clinical effects [2,4,5].  
MPH has a dual pharmacological profile inhibiting the reuptake of both 
dopamine (DA) and noradrenaline (NE) by blocking their respective transporters 
(DAT and NET respectively) [6-8]. This consequently increases the bioavailability of 
synaptic DA and NE [9,10]. MPH has also a weak affinity for the 5-HT1A receptor, 
where in vitro studies have suggested that it acts as a partial agonist [8]; however, to 
date there has been no clear evidence of target engagement in vivo. On the other 
hand, effects on DAT and NET have been well documented in a rich diversity of in-
vitro, animal and human studies [6]. Despite this, it remains unclear whether the 
functional effects of MPH are best understood through DAT or NET binding (for a 
detailed review please see [6]). Studies evaluating in-vitro activity for both these 
neurochemical transporters seem to agree that the racemic mixture dl-MPH typically 
used in clinical formulations have higher affinity and uptake inhibition activity on the 
DAT than the NET [6]. In-vivo human positron emission tomography (PET) studies 
have also shown a clear accumulation of MPH in the basal ganglia and binding to 
DAT (ED50 = 0.25 mg/kg) [11,12]. However, in the living human brain MPH has also 
been shown to bind to NET (ED50 = 0.14 mg/kg) with a higher affinity than to DAT 
[13,14].  
A similar issue relates to effects of MPH on human cognition and brain function. 
Again, it is unclear whether effects mostly relate to binding to DAT, NET or both 
systems, and whether effects on different regional circuits are related to the 
engagement of these two targets, given the known differences in their distribution 
densities [15-19]. Several studies have combined acute administration of MPH  with 
functional magnetic resonance imaging (fMRI) in both healthy and clinical 
populations to try and unravel potential effects on brain function and gain a clearer 
understanding of its effects on behaviour [2,4]. These studies have employed both 
resting state designs and task-based approaches that tap into specific cognitive 
constructs. Pharmacological resting state fMRI (rs-fMRI) allows for the evaluation of 
basic pharmacodynamical effects unconstrained by the nature of any task and have 
been widely used [20,21]. Studies in healthy individuals have shown that acute 
administration of clinically relevant MPH doses induce measurable and meaningful 
changes in functional connectivity (FC). For example, one study found an MPH-
associated increase in intrinsic connectivity between brain areas involved in 
sustained attention [22]. Another reported that MPH enhanced resting state FC of the 
striatum/thalamus with primary motor cortex and increased negative FC with frontal 
executive regions [23]. In another, MPH was shown to reduce the coupling within 
visual and somatomotor networks and increase the competitive decoupling between 
the default mode and task positive networks [24]. However, given that the blood-
oxygen level dependent (BOLD) signal underpinning fMRI studies has no intrinsic 
selectivity to any particular neurochemical target [25,26], it is still unclear which MPH 
pharmacological targets underpin observed changes in brain FC.  
To bridge this gap, we have previously developed a novel multimodal method 
(Receptor-Enriched Analysis of functional Connectivity by Targets - REACT) which 
enriches rs-fMRI analyses with information about the distribution density of molecular 
targets derived from PET imaging. Further, we have shown that the functional effects 
of 3,4-Methyl-enedioxy-methamphetamine (MDMA) can be understood through the 
distribution of its main serotonergic targets [27]. Here, we applied REACT to multi-
echo rs-fMRI data acquired in a cohort of healthy participants after an acute 
challenge of MPH to investigate how drug-related changes in resting state FC relate 
to the distribution of the DAT and NET. Given the considerable affinity of MPH to both 
transporters [2], we hypothesised that FC informed by these two targets would be 
sensitive to MPH effects.  
We also performed an exploratory analysis to test whether MPH-induced 
changes in the DAT- and NET-enriched FC can be linked to inter-individual 
differences in behavioural responses on a reinforcement-learning task with known 
sensitivity to MPH (results for the main effects of this task are reported elsewhere 
[28]). Multiple fMRI studies have shown that inter-individual differences in behavioural 
responses to a task can be related to individual differences in spontaneous cortical 
activity at rest [29,30]. Our hypothesis is that by using the functional maps related to 
the MPH targets, we can link inter-individual variability in behavioural response to the 
task with the resting state FC and tease apart the variability associated with DAT and 
NET. 
 
METHODS 
Participants and study design 
In this work, we used the resting state fMRI dataset from a larger study on 
ADHD, of which the task-based fMRI data have already been published elsewhere 
[28]. We included data from thirty healthy controls (HC, 33 ± 9.5 years, M/F: 19/11). 
Participants were recruited using on-line classified advertising websites and 
university mailing lists. Local and national ethical approvals were obtained from 
Brighton and Sussex Medical School (14/014/HAR; 12/131/HAR) and the East of 
England (Hertfordshire) National Research Ethics Committee (reference: 
12/EE/0256). All participants provided written informed consent. We excluded all 
potential participants if they had any self-reported psychiatric disorders, substance 
abuse, history of serious cardiovascular condition, current or recent use of 
monoamine oxidase inhibitors, coumarin anticoagulants, anticonvulsants or 
antipsychotics, if they had a diagnosis of glaucoma or were pregnant. Upon 
enrolment to the study, the Beck Depression Inventory (BDI) [31] and the State and 
Trait Anxiety Inventory [32] were used to assess depression and anxiety scores, 
respectively.  
We followed a randomized, within-subjects, double-blind, placebo-controlled 
design where participants received 20 mg of oral MPH or placebo in two separate 
sessions, spaced by a minimum of 1 week. This dose of MPH is at the lower end of 
the clinical dose and allow us to evaluate functional effects in the brain within a 
clinically relevant dose while keeping potential side effects at minimum. All 
participants were tested at the same time of day for both the MPH and placebo 
session, to minimise potential circadian variability in resting brain activity [34]. 
 
We excluded one subject because of excessive head movement during the 
placebo session (mean relative displacement > 0.2 mm). 
Image acquisition 
Ninety minutes after drug dosing, participants completed an MRI session, to 
coincide with peak effects of MPH on DAT occupancy [12]. The session 
included a 9-minute multi-echo rs-fMRI scan. The rs-fMRI scan was used for the 
analysis presented here. Prior to the resting state scan were three runs of a 
reinforcement-learning task encompassing a novelty manipulation [35,36], 
which is reported in detail elsewhere [28]. For the purpose of this work we 
use the behavioural outcome of the task independent of the fMRI data 
concurrently acquired.  
Data were acquired using a 1.5 T Siemens Avanto MRI scanner (Siemens AG 
Medical Solutions, Erlangen, Germany) equipped with a 32-channel head-coil. Rs-
fMRI data were obtained using a T2*-weighted multi-echo EPI sequence [37] (TR = 
2570 ms; TEs = 15, 34, 54 ms; flip angle = 90⁰; resolution = 3.7 × 3.75, slice thickness 
= 4.49 mm; matrix size = 64 x 64; 31 axial slices; 200 volumes). A 3D T1-weighted 
anatomical scan was obtained for each participant in one session using an MP-RAGE 
acquisition (TR = 2730 ms, TE = 3.57 ms, TI = 1000 ms, flip angle = 7⁰, matrix = 256 
x 240, number of partitions = 192, GRAPPA factor = 2, resolution = 1 mm3).  
Image pre-processing  
The rs-fMRI dataset was pre-processed using AFNI [38] and FMRIB Software 
Library (FSL). Pre-processing steps included volume re-alignment, time-series de-
spiking and slice time correction. After the pre-processing, functional data were 
optimally combined (OC) by taking a weighted summation of the three echoes using 
an exponential T2* weighting approach [39]. The OC data were then de-noised with 
the Multi-Echo ICA (ME-ICA) approach implemented by the tool meica.py (Version 
v2.5) [40,41], to remove motion artefacts and other non-BOLD sources of noise. This 
de-noising method has proved its greater effectiveness in reducing non-BOLD 
sources of noise and increasing the temporal signal-to-noise ratio when compared to 
other standard regression approaches [41-43]. White matter and cerebrospinal fluid 
signals were regressed out and a high-pass temporal filter with a cut-off frequency of 
0.005 Hz was applied. 
A study-specific template representing the average T1-weighted anatomical 
image across subjects was built using the Advanced Normalization Tools (ANTs) 
[44]. Each participant’s dataset was co-registered to its corresponding structural 
scan, then normalized to the study-specific template before warping to standard 
MNI152 space. Images were finally resampled at 2×2×2 mm3 resolution. 
Population-based molecular templates 
For the analysis with REACT, we used molecular templates of the DAT and 
NET systems. The DAT map is a publicly available template of 123I-Ioflupane SPECT 
images (https://www.nitrc.org/projects/spmtemplates) from 30 HC without evidence 
of nigrostriatal degeneration [45]. The NET atlas was obtained by averaging the 
[11C]MRB PET brain parametric maps from an independent dataset of 10 HC (33.3 
+/- 10 years, four women). More details on the processing of the PET data and 
regional distribution of [11C]MRB binding in the human brain can be found in [46]. 
These two atlases were already standardised to MNI space with 2 mm3 resolution. 
They were further normalised to scale the image values between 0 and 1, while 
preserving the original intensity distribution of the images, and masked using a 
standard grey matter (GM) mask. This mask comes from a probabilistic GM map 
available in FSL, which we thresholded in order to retain only the voxels with >30% 
probability of being GM, and binarized. Of note, occipital areas (defined using the 
Harvard Oxford Atlas) were masked out of both molecular atlases as they were used 
as reference regions for quantification of the molecular data in the kinetic models for 
the radioligands. 
Functional connectivity analysis with the REACT method 
The functional circuits related to the DAT and the NET systems were estimated 
with REACT using a two-step multivariate regression analysis [47,48] implemented in 
FSL (fsl_glm command). This analysis is conceptually comparable to a dual-
regression, often used in rs-fMRI studies to investigate the FC of the resting state 
networks. The main difference with this standard approach is that, with REACT, 
molecular templates are used in place of the resting state networks as a set of spatial 
regressors in the first multivariate regression analysis. The DAT and NET templates 
are entered into the first step of this analysis to calculate the dominant BOLD 
fluctuation within these maps [49]. Both rs-fMRI data and the design matrix were 
demeaned (--demean option). The rs-fMRI volumes were masked using a binarized 
atlas derived from the molecular data to restrict the analysis to the voxels for which 
the transporter density information was available in the template. The subject-specific 
time series estimated in this first step were then used as temporal regressors in a 
second multivariate regression analysis to estimate the subject-specific spatial maps 
of the BOLD response after MPH and placebo. At this stage, the analysis was 
conducted on the whole grey matter volume. Both data and the design matrix were 
demeaned (--demean option); the design matrix columns were also normalised to 
unit standard deviation with the --des_norm option [47]. The general framework of 
this analysis has been reported elsewhere [27].  
Statistical analysis 
In order to test our main hypothesis, we ran a paired-sample t-test to compare 
the subject-specific target-enriched spatial maps of the two drug conditions (MPH 
and placebo). We applied cluster-based inference within Randomise [50], using 
5000 permutations per test and contrast. A cluster was considered significant if pFWE 
< 0.05, corrected for multiple comparisons using the threshold-free cluster 
enhancement (TFCE) option [51], Bonferroni-corrected for multiple comparisons 
across maps (DAT and NET) and contrasts (MPH > placebo, placebo > MPH). 
We also conducted some further post-hoc analyses to explore whether there 
were any areas of the brain where our DAT and NET-enriched FC maps were related 
to some of the key-behavioural responses elicited during the task the subjects 
performed immediately before the resting state scan (a detailed description of these 
behavioural responses can be found in [28]; here we summarize only those we used 
in our analyses). For this, we conducted a set of linear regression analyses between 
the target-enriched FC maps (MPH minus placebo) and four behavioural scores: 1) 
overall task performance (total £ won during the task); 2) reward-learning rate (a 
mathematical quantity resulting from fitting of a reinforcement learning model [36] to 
participants’ behavioural responses, which captures the extent to which choice is 
updated by recently gathered evidence; a higher score reflects faster updating of 
reward values with recent experience); 3) persistence in selecting novel options after 
their first appearance; 4) persistence in selecting novel rather than familiar stimuli 
after their first appearance (these last two behavioural measures capture novelty 
preference). For each regression analysis, we used the difference between scores 
on active drug and placebo (MPH minus Placebo). These tests were also performed 
with Randomise using 5000 permutations per test and contrast. For the significant 
correlations, we then extracted the mean FC value (MPH minus Placebo) from the 
clusters we found to be significantly associated with the behavioural responses in 
order to estimate the Pearson correlation coefficient using SPSS. Please note, these 
values are simply presented as a measure of effect size. We did not conduct 
statistical inference as such analysis would be circular. 
 
RESULTS 
In Figure 1, we show the templates of the molecular density distribution of the 
DAT (left panel, top row) and NET maps (right panel, top row) that we used in the 
REACT analysis. We also show the weighted-maps of their respective functional-
associated circuits for each drug condition, averaged across participants. 
 
 
Fig. 1 Maps of the molecular templates of the dopamine and noradrenaline transporters (DAT 
and NET) and their respective target-enriched fMRI maps. The fMRI maps are averaged 
across subjects for the placebo and methylphenidate (MPH) conditions. The occipital areas 
were masked out for both molecular atlases as they were used as reference regions for the 
quantification of the molecular data in the kinetic models for the radioligands. For more details 
on the molecular templates, please refer to [45,46].  
 
We found a significant increase in FC (pFWE < 0.05, corrected for multiple 
comparisons at the cluster level using the threshold-free cluster enhancement (TFCE) 
option, Bonferroni-corrected for multiple comparisons across maps and contrasts) 
after MPH in the maps enriched by the DAT distribution (Fig. 2). Specifically, this 
effect mainly involved sensorimotor areas including the precentral and postcentral 
gyri and the anterior division of the supramarginal gyrus. No changes between MPH 
and placebo were found in the NET-enriched FC maps.  
 
 
Fig. 2 Functional connectivity (FC) changes after MPH compared to placebo in the DAT-
enriched maps. The MPH-induced FC increase is localised in the precentral and postcentral 
gyri and the anterior division of the supramarginal gyrus. 
Relationship between drug-induced functional changes at rest and 
behavioural responses during the novelty reinforcement learning task 
We found significant negative correlations between persistence in selecting 
novel options after their first appearance (MPH minus placebo) and the MPH-induced 
functional changes in the DAT and the NET-enriched FC maps (MPH minus placebo). 
Specifically, we found a negative correlation between DAT-enriched FC and this 
behavioural score in the cerebellum, i.e. the right crus I and II, the right VI and VIIb 
and the vermis crus II (r = -0.739, 95% CI = -0.865 to -0.542; Fig. 3A). For the NET-
enriched FC, this correlation mainly involved the precentral gyrus, the posterior 
cingulate cortex and precuneus (r = -0.687, 95% CI = -0.831 to -0.488; Fig. 3A). 
We also found a positive association between FC changes induced by MPH in the 
NET-enriched maps and task performance (£ won) in the lateral occipital cortex, 
precuneus and superior parietal lobule (r = 0.753, 95% CI = 0.590 to 0.857; Fig. 3B). 
We did not find any other significant correlation for any of the remaining behavioural 
measures tested. 
 
Fig. 3 Correlations between behavioural response and functional connectivity (FC). Panel A: 
Persistence in selecting novel rather than familiar stimuli after their first appearance (MPH 
minus placebo) is inversely correlated with FC changes (MPH minus placebo) in the DAT-
enriched and NET-enriched FC maps. Panel B: Task performance (i.e., £ won) (MPH minus 
placebo) is positively correlated with functional increases in the NET-enriched FC maps. 
DISCUSSION 
In this study, we applied our recently developed multimodal method for FC 
analysis informed by molecular targets (REACT) to investigate how drug-related 
changes in resting FC after a single administration of MPH in healthy individuals relate 
to the distribution of its main targets, i.e. the DAT and NET. In line with our main 
hypothesis, we found that MPH changed connectivity within the functional network 
related to the DAT. However, we did not find any significant drug-effects related to 
the NET distribution at the robust statistical thresholds reported here. Furthermore, 
we found that different regional changes in the DAT and NET-enriched FC maps can 
significantly explain some of the inter-individual variance in participants’ behaviour 
during a novelty reinforcement learning task engaging both systems [52]. Moreover, 
we have extended our method validation pipeline by showing that REACT is able to 
capture meaningful changes in the target-enriched functional circuits beyond those 
related to the serotonin system, which we reported in our first proof-of-concept work 
[27].  
In the main analysis, we were able to show that MPH effects on resting FC co-
vary with the known distribution of one of its main targets, the DAT. We found FC 
increases within the DAT-related network mapping somatomotor areas, such as the 
precentral and postcentral gyri and the anterior division of the supramarginal gyrus. 
This overlaps with regions where regional cerebral blood flow measured at rest is 
modulated by a single dose of MPH as part of a pattern which also includes the 
caudate nucleus, thalamus and mid-brain, as reported in [53], all areas enriched in 
DAT. Our findings are also consistent with previous observations in healthy 
individuals that MPH increases the FC between the striatum (a brain region highly 
enriched in DAT) and the somatomotor cortex [23]. Our results also mirror previous 
studies where levodopa and haloperidol (pro- and anti-dopaminergic drugs, 
respectively) were found to modulate the resting state and task-related FC between 
the motor cortex and the striatum in healthy participants [54,55], and another study 
where acute phenylalanine and tyrosine depletion method used to decrease DA 
synthesis decreased FC within the somatomotor network [56]. While our data was 
acquired at rest, and therefore making inferences about the potential behavioural 
implications of such findings is inherently speculative, we note that the FC increase 
in the somatomotor cortex is in line with some reported effects of MPH and other 
catecholaminergic agents on motor performance [57]. For instance, MPH has been 
shown to improve motor functions in clinical conditions encompassing motor deficits. 
In fact, a single dose of MPH has been shown to improve motor coordination in 
children with developmental coordination disorder and ADHD [58], and low doses of 
this drug have been reported to improve gait and voluntary movement in patients with 
Parkinson disease [59]. While the implications of these findings for the improvements 
in motor coordination observed in patients with ADHD after MPH are relatively intuitive 
to extrapolate, their contribution to better understanding the effects of MPH on other 
symptoms-domains, such as impulsivity or inattention, is less straightforward.  
Recent computational modelling approaches attempting to establish a single 
parsimonious model to explain all of the core symptomatology of ADHD have 
suggested that signal loss due to low neural gain in the corticostriatal loops might be 
at the heart of the behavioural manifestations of this disorder [60]. Here, neural gain 
is a process through which the brain amplifies incoming signals according to their 
momentary importance [61]. In high neural gain states, neural populations amplify 
strong signals and attenuate weaker ones, leading to neural representations that are 
less susceptible to noise and serve to stabilize behaviour. In contrast, low neural gain 
states are associated with behavioural instability [60]. Conceptually, inattention can 
be conceptualised as a frequent shift between different competing goals and an 
inability to focus and stay with the currently most valuable option. Likewise, frequent 
switches between cognitive goals might propagate through the motor system and 
lead to frequent changes in motor programs, potentially explaining hyperactivity.  
Therefore, impaired neural gain in corticostriatal loops during action selection 
has the potential to explain the instable behavioural patterns underlying both 
inattention and hyperactivity in patients with ADHD [60]. A key modulator of neural 
gain within these corticostriatal loops is DA, as it modulates the strength of information 
conveyed from the cortex (including the sensorimotor cortex), via the striatum, 
through the internal pathways of the basal ganglia [61]. Under low DA, signal 
differentiation between the direct and indirect pathways of the loops are comparable 
in strength, resulting in signal interference and behavioural instability. Following this 
concept, decreases in DA could account for the behavioural instability observed in 
ADHD [60]. Indeed, this DA decrease has been shown in PET studies [62].  
Conversely, increases in DA strengthen signal differentiation in the direct 
pathway, suppressing noise, stabilising neural systems and behavioural patterns. 
Therefore, it is possible that the increased DAT-related connectivity in the 
somatomotor cortex that we report here reflects MPH-induced strengthening of neural 
gain in the direct pathway through a tonic increase in DA. If that is true, our findings 
in healthy individuals might reflect a basic pharmacological mechanism through 
which MPH can improve motor coordination, inattention and hyperactivity in patients 
with ADHD by modulating DAergic transmission. However, we must acknowledge 
that for now this hypothesis remains speculative and will need to be addressed in 
future empirical studies. 
The lack of findings for the NET-enriched functional circuit is surprising for a 
number of reasons. First, human PET studies have shown that at clinical doses (such 
as those used here), MPH binds to the NET with a higher affinity than to the DAT 
[13,14]. Second, there is further evidence from studies in experimental animal 
showing that MPH can directly affect the discharge properties of the locus coeruleus 
(LC) [63], which is the main source of noradrenergic innervation in the brain. These 
findings are also supported by a rs-fMRI study in humans showing that MPH exerts 
effects on the FC of the LC [64]. Third, there is a general consensus that the MPH 
pro-cognitive effects in ADHD patients and HC involve modulation of the prefrontal 
cortex (PFC) [65]. While both DA and NA have critical influence on PFC cognitive 
functioning [65,66], there are relatively low levels of DAT in the PFC [67], supporting 
the hypothesis that MPH and other psychomotor stimulants effects in this area may 
involve NET inhibition [68]. However, a number of reasons can be advanced to 
explain this lack of findings in the NET-related FC. First, there may be a limitation in 
our technique. We use the available binding sites for NET, but PET occupancy studies 
suggest a regional variation in the MPH occupancy of NET [13] which would weigh 
more towards the effects at the LC which may be poorly represented in the MRI maps 
acquired at 1.5 or 3T [69]. A general limitation that we should also consider is that 
our subjects performed a reinforcement learning task – which is known to elicit a 
dopaminergic response [70] – immediately before the rs-fMRI scan, and that this may 
have induced some carry-over effects biasing FC towards the DAT-related network. 
Furthermore, it is also important to point out that the reuptake of dopamine and 
noradrenaline is complex, as both transporters can participate in the reuptake of both 
DA and NA [71,72]. This implies that MPH could still affect noradrenergic 
transmission through DAT inhibition. Moreover, we cannot exclude that some NET-
related FC changes that do not reach statistical significance at rest may emerge 
during a paradigm preferentially engaging attentional networks [73,74]. Finally, we 
acquired data on a single time-interval post-dosing with a single low dose. PET 
occupancy of 10mg and 40mg MPH at NET assessed in vivo using [11C]MRB 
indicates that this dose is sufficient to produce a significant NET occupancy with  
robust peak effects between 75 minutes and at least 3 hours post-dosing [14]. 
Although MPH did not elicit robust behavioural responses during the novelty-
reinforcement learning task in HC (data published elsewhere [28]), our exploratory 
analysis highlighted that regional differences between MPH and placebo on DAT- 
and NET-enriched FC are significantly correlated with inter-individual differences in 
the MPH-induced changes in key-behavioural responses associated with this task. 
Indeed, our findings show that despite the relatively low density of DAT in the 
cerebellum, the DAT-enriched connectivity in this same area was related to 
performance. This may be related to the strong anatomical connectivity between the 
cerebellum and the DAT-enriched basal ganglia [75], or it may relate to direct effects 
within the cerebellum. Despite the low detection of DAT availability in vivo in humans, 
DAT is present in the cerebellum [76] and our findings match current models 
suggesting a role of the cerebellum in error/novelty detection [77-79].  
While we did not find a treatment effect of MPH in the NET-related FC, we did 
find a positive association between FC changes induced by MPH in the NET-enriched 
maps and overall task performance (£ won) in the lateral occipital cortex, precuneus 
and superior parietal lobule. We also found negative correlations between 
persistence in selecting novel rather than familiar options and NET-enriched FC 
changes induced by MPH mainly in the precentral gyrus, the posterior cingulate 
cortex and the precuneus. Consistent with our findings, these areas have previously 
been shown to be implicated in novelty processing [80-82]. Animal studies have 
shown that the occipital and parietal cortices receive a dense noradrenergic 
innervation and that pharmacological NET blockade increases extracellular NE (but 
not DA) in these areas [83,84]. Furthermore, a resting state fMRI study in healthy 
subjects reported a FC decrease induced by atomoxetine, i.e. a relatively selective 
NET blocker, predominantly in the posterior brain regions including the visual system 
[85]. Another fMRI study using a n-back task in healthy volunteers reported 
atomoxetine-induced FC changes in the frontoparietal network, including areas such 
as the precentral gyrus and the precuneus, during working-memory processing [86].  
Although preliminary, our findings suggest that REACT may hold the potential 
to tease apart regional functional effects related to different molecular targets 
underlying the same cognitive/behavioural downstream effect when compounds like 
MPH binding with considerable affinity to more than one molecular target are used. 
However, since we relied on correlations between resting state FC and behavioural 
measures acquired at a different time point, this hypothesis would benefit from further 
development of REACT to accommodate task-based designs. 
Our study has some limitations to acknowledge. First, we did not collect blood 
samples and assay plasma levels of MPH to control for individual differences in drug 
exposure or to explore pharmacokinetic/pharmacodynamic relationships. Second, 
while the original study also included patients with ADHD [28], we only report data 
from the healthy control group, where all participants received the same drug at the 
same dose; therefore, the implications of our findings should not be generalized to 
clinical populations. However, we decided to not include the ADHD dataset because 
all patients were on chronic stimulant treatment, which is known to produce long-
lasting changes in baseline DAT bioavailability [87,88]. Furthermore, ADHD patients 
were tested under their routine treatment, which was heterogeneous (i.e. either MPH 
or dexamphetamine). These two factors would have made interpretation of potential 
findings challenging. Third, stimulants can potentially influence fMRI BOLD signal, 
which depends on the haemodynamic coupling of neuronal activities and local 
changes in blood flow and oxygenation [25]. However, previous work has found that 
while stimulants can decrease cortical blood flow, they do not obscure BOLD signals 
or disrupt neurovascular coupling during resting brain activity [89]. Finally, we relied 
on group-based molecular templates estimated in two independent cohorts of 
healthy individuals. Therefore, further specification from intra-regional variation 
across subjects is not possible using the current dataset as it would require PET data 
for each ligand and participant. Nevertheless, it would be interesting to test whether 
subject-specific receptor density maps would provide additional information. This last 
aspect may be critical in moving forward to examine MPH-induced FC changes in 
clinical populations (i.e. ADHD), who may have alterations in the distribution of DAT 
[88] and NET [90]. 
 
CONCLUSION 
Using our recently developed multimodal method for FC analysis informed by 
molecular targets (REACT), we show that meaningful MPH effects on human brain 
resting FC can be understood through the distribution of, at least, one of its main 
targets, i.e. DAT. We also provide evidence to support the idea that this method may 
be able to capture concomitant differential regional functional effects related to 
different targets underlying the same cognitive/behavioural effect, when compounds 
have mixed pharmacological profiles. By defining the target-specific topography of 
the functional effects of pharmacological compounds in the human brain, our method 
holds the potential to advance our understanding of the mechanisms of action of 
many drugs for which target affinity is relatively well characterized but system-level 
brain pharmacodynamic models related to their targets are missing. 
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